Muhammad Siddiqui, MD
Hospice and Palliative Medicine · Manassas, VANPI 1093953168
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $560 and has fallen 83.5% since, to $92 in 2025.
Across 38 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$130
- Regeneron Healthcare Solutions, Inc.$120
- AstraZeneca$80
- Johnson & Johnson$78
- Stemline Therapeutics Inc.$76
- Daiichi Sankyo Inc.$72
- plus $393 from 13 others
What the payments were for
- Food & beverage$948100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $130 |
| Regeneron Healthcare Solutions, Inc. | 4 | $120 |
| AstraZeneca | 4 | $80 |
| Johnson & Johnson | 3 | $78 |
| Stemline Therapeutics Inc. | 2 | $76 |
| Daiichi Sankyo Inc. | 3 | $72 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $60 |
| Pharmaessentia USA Corporation | 1 | $35 |
| AbbVie | 1 | $35 |
| Ardelyx, Inc. | 2 | $35 |
| Myriad Genetic Laboratories, Inc. | 2 | $33 |
| Amgen | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| EMD Serono, Inc. | 1 | $25 |
| Tersera Therapeutics LLC | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Beigene USA, Inc. | 1 | $22 |
| Merck | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
How this compares
$948 in reported general payments places this provider in the 85th percentile of 45 hospice and palliative medicine providers in Virginia.
See all hospice and palliative medicine providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 20 | $13,279 |
| JanuviaSitagliptin Phosphate | 18 | $7,813 |
| Xtampza ErOxycodone Myristate | 12 | $6,223 |
| Pregabalin | 91 | $5,189 |
| Fentanyl | 51 | $4,751 |
| Hydromorphone ErHydromorphone Hcl | 18 | $4,251 |
| Oxycodone Hcl | 280 | $4,057 |
| Gabapentin | 216 | $3,516 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 154 | $3,452 |
| Morphine Sulfate ErMorphine Sulfate | 110 | $2,668 |
| Duloxetine Hcl | 52 | $1,296 |
| Tramadol Hcl | 90 | $1,071 |
| Mirtazapine | 41 | $1,042 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $871 |
| Hydromorphone Hcl | 70 | $828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $22 | $7,81318 claims |
| Lilly USA, LLCOlanzapine | $24 | $30029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 hospice and palliative medicine providers in Virginia.
Other hospice and palliative medicine in Manassas
- Gregory AloufSalem$13K
- Purvi ShahRichmond$9K
- Sarah WestNewport News$3K
- Jessica HeintzFairfax$2K
- Sea KimAlexandria$2K
- Haley VestCharlottesville$534
- Cara JenningsRichmond$458
- Ying LiNorfolk$240
- Prashanta KoiralaWinchester$235
- Ryen ButlerFredericksburg$230
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.